title: A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr follow-up study.
abstract: OBJECTIVE
  To compare the efficacy and side effects of standard bismuth triple therapy with those of omeprazole-based triple therapy in patients with Helicobacter pylori infection and duodenal ulcer disease.
  
  
  METHODS
  One hundred patients were prospectively recruited and randomized to receive either bismuth subnitrate 75 mg q.i.d., oxytetracycline 500 mg q.i.d., and metronidazole 400 mg b.i.d. (regimen BTM), or omeprazole 20 mg b.i.d., amoxicillin 750 mg b.i.d., and metronidazole 400 mg b.i.d. (regimen OAM), both for 14 days. Upper endoscopy (with antral biopsy specimens for microbiology and antral and corpus biopsy specimens for histology) was performed before treatment, after 2 months, and again 1 yr after treatment. Serum samples for serology (IgG) were taken. Patients with in vitro metronidazole-resistant (M-R) H. pylori strains were excluded. In a nonrandomized study, 41 patients with M-R strains were given either BTM or OAM.
  
  
  RESULTS
  According to intention-to-treat analysis, H. pylori cure rates were 91% and 96% with BTM and OAM, respectively (p = 0.45). In the BTM group, the mean total side effect score was higher (p < 0.001), and more severe side effects were reported (32% vs. 4%, p < 0.001). In the nonrandomized group of patients with M-R strains, H. pylori cure rates were 88% and 67% with BTM and OAM, respectively. All of the successfully treated patients were still H. pylori-negative after 1 yr.
  
  
  CONCLUSIONS
  Both treatment regimens were highly effective in curing H. pylori infection in patients with metronidazole-sensitive strains. Omeprazole-based triple therapy was tolerated better than standard bismuth-based triple therapy.
authors.affiliation: Department of Internal Medicine, Ostfold Central Hospital, Fredrikstad, Norway.
authors.forename: F
authors.initials: F
authors.lastname: Lerang
authors.forename: B
authors.initials: B
authors.lastname: Moum
authors.forename: E
authors.initials: E
authors.lastname: Ragnhildstveit
authors.forename: J B
authors.initials: JB
authors.lastname: Haug
authors.forename: T
authors.initials: T
authors.lastname: Hauge
authors.forename: P
authors.initials: P
authors.lastname: Tolås
authors.forename: E
authors.initials: E
authors.lastname: Aubert
authors.forename: M
authors.initials: M
authors.lastname: Henriksen
authors.forename: P S
authors.initials: PS
authors.lastname: Efskind
authors.forename: K
authors.initials: K
authors.lastname: Nicolaysen
authors.forename: T
authors.initials: T
authors.lastname: Søberg
authors.forename: A
authors.initials: A
authors.lastname: Odegaard
authors.forename: T
authors.initials: T
authors.lastname: Berge
mesh_terms: D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000009:adverse effects / Q000627:therapeutic use; D000863:Antacids / Q000009:adverse effects / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001729:Bismuth / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009853:Omeprazole / Q000009:adverse effects / Q000627:therapeutic use*; D010118:Oxytetracycline / Q000009:adverse effects / Q000627:therapeutic use; D010406:Penicillins / Q000627:therapeutic use; D011446:Prospective Studies; D012008:Recurrence; D013997:Time Factors
chemical_list: D000863:Antacids; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D010406:Penicillins; D008795:Metronidazole; D000658:Amoxicillin; C010804:bismuth subnitrate; D009853:Omeprazole; D001729:Bismuth; D010118:Oxytetracycline